

Express Mail Label N . EL 831678235 US
Date of Deposit: October 4, 2001

COPY

Page 1 of 2


OCT 09 2001
TECH CENTER 1600/2900

Modified Form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| | |
|------------------------|---------------------|
| Application Number | 09/724,842 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Chalifour |
| Group Art Unit | Not Yet Assigned |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | 14445-501 (NCHEM-1) |



U.S. PATENT DOCUMENTS

| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
|---------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| ST | A7 | 5,753,624 | 05/19/98 | McMichael <i>et al</i> | 514 | 12 | |
| | A8 | 5,514,548 | 05/07/96 | Krebber <i>et al</i> | 435 | 6 | |
| | A9 | 5,869,093 | 02/09/99 | Weiner <i>et al</i> | 424 | 451 | |
| | A10 | 5,470,951 | 11/28/95 | Roberts | 530 | 330 | |
| ST | A11 | 5,652,334 | 07/29/97 | Roberts | 530 | 330 | |

FOREIGN PATENT DOCUMENTS

| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes | No |
|---------------|----------|---------------------------------------|-------------------------------------|---------------------|-----------------|----|
| ST | B11 | WO 95/05849 | M&E Biotech A/S | 02/03/95 | | |
| | B12 | WO 00/20027 | M&E Biotech A/S | 13/04/00 | | |
| | B13 | EP 0752886B1 | M&E Biotech A/S | 28/01/98 | | |
| | B14 | WO 95/31996 | Milkhaus Laboratory | 30/11/95 | | |
| | B15 | WO 95/05393 | Hoess <i>et al.</i> | 23/02/95 | | |
| | B16 | WO 96/13583 | Pack <i>et al</i> | 09/05/96 | | |
| | B17 | WO 98/02462 | Plückthun | 22/01/98 | | |
| | B18 | WO 99/06587 | Rudert <i>et al.</i> | 11/02/99 | | |
| | B19 | WO 97/32017 | Ilag <i>et al.</i> | 04/09/97 | | |
| | B20 | WO 97/08320 | Knappik <i>et al.</i> | 06/03/97 | | |
| | B21 | WO 00/68263 | Neurochem Inc. | 16/11/00 | | |
| | B22 | WO 98/08868 | Praecis Pharm Inc. | 05/03/98 | | |
| | B23 | WO 96/28471 | Pharmaceutical Peptides Inc. | 19/09/96 | | |
| | B24 | WO 97/21728 | Karolinska Innovations AB | 19/06/97 | | |
| | B25 | WO 95/08999 | Roberts | 06/04/95 | | |
| ST | B26 | WO 96/37621 | Pack <i>et al.</i> | 28/11/96 | | |



TECH CENTER 1600/2900

RECEIVED
OCT 09 2001

| OTHER NON PATENT LITERATURE DOCUMENTS | | |
|---------------------------------------|----------|---|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| 8 | C1 | Younkin, "Amyloid beta vaccination: reduced plaques and improved cognition", Nat. Med. 2001 Jan; 7(1):18-9. |
| | C2 | Morgan <i>et al.</i> , "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature, 2000 Dec. 21-28;408(6815):982-5. |
| | C3 | Pearson <i>et al.</i> , "Beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," Nature, 2000 Dec. 21-28; 408(6815):979-82. |
| | C4 | Schenk <i>et al.</i> , Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 1999 Jul. 8; 400(6740):173-7. |
| | C5 | Bard <i>et al.</i> , "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nat. Med. 2000 Aug; 6(8):916-9. |
| | C6 | DeMattos <i>et al.</i> , "Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease," Proc. Natl. Acad. Sci. USA 2001 Jul. 3 [ebpub ahead of print] |
| | C7 | Frenkel, "Immunization against Alzheimer's beta-amyloid plaques via EFRH phageadministration," Proc. Natl. Acad. Sci. USA 2000 Oct. 10;97(21):11455-9. |
| | C8 | Frenkel, "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine 2001 Mar. 21;19(17-19):2615-9. |
| | C9 | Van Regenmortel <i>et al.</i> , "D-peptides as immunogens and diagnostic reagents," Curr. Opin. Biotechnol. 1998; Aug; 9(4):377-82. |
| | C10 | Sela <i>et al.</i> , "Different roles of D-amino acids in immune phenomena," FASEB J 199 May; 11(6):449-56. |
| | C11 | Tjernberg, <i>et al.</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 Jul. 11; 272(28):17894. |
| | C12 | Tjernberg <i>et al.</i> , "Arrest of beta-amyloid fibril formation by a pentapeptide ligand," J. Biol. Chem. 1996 Apr. 12; 271(15):8545-8. |
| | C13 | Tjernberg, <i>et al.</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 May 9; 272(19):12601-12605. |
| | C14 | Giulian, "The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer disease," J. Biol. Chem. 1998 Nov. 6; 273 (45):29719-29726. |
| | C15 | Flood <i>et al.</i> , "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic affect of amyloid B protein," Proc. Natl. Acad. Sci. USA 1994; 91:380-384. |
| | C16 | Findeis <i>et al.</i> , "Modified peptide inhibitors of amyloid B-peptide polymerization," Biochemistry 1999; 38:6791-6800. |
| | C17 | Benkirane <i>et al.</i> , "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," The Journal of Biological Chemistry 1993; 268 (23):26279-26285. |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 8-27-02 |
|--------------------|--|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.